Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 261-271 , April 2009

Pathogenesis of adrenocortical cancer

References 

  1. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Annals of Internal Medicine. 2003;138:424–429
  2. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine. 1990;322:1195–1201
  3. Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clinical Endocrinology (Oxford). 2004;60:273–287
  4. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism. 2006;91:2650–2655
  5. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer. 2007;14:13–28
  6. Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology. 2005;153:477–487
  7. Gicquel C, Leblond-Francillard M, Bertagna X, et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clinical Endocrinology (Oxford). 1994;40:465–477
  8. Beuschlein F, Reincke M, Karl M, et al. Clonal composition of human adrenocortical neoplasms. Cancer Research. 1994;54:4927–4932
  9. Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 2002;87:3467–3474
  10. Kjellman M, Kallioniemi OP, Karhu R, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Research. 1996;56:4219–4223
  11. Kjellman M, Roshani L, Teh BT, et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. Journal of Clinical Endocrinology and Metabolism. 1999;84:730–735
  12. Zhao J, Speel EJ, Muletta-Feurer S, et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. American Journal of Pathology. 1999;155:1039–1045
  13. Dohna M, Reincke M, Mincheva A, et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer. 2000;28:145–152
  14. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research. 2001;61:6762–6767
  15. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 1992;4:1–15
  16. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute. 1998;90:606–611
  17. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528–2531
  18. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute. 1994;86:1707–1710
  19. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. American Journal of Human Genetics. 1999;65:995–1006
  20. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:9330–9335
  21. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 2001;86:4970–4973
  22. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Structural Biology. 2002;9:12–16
  23. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. International Journal of Cancer. 1993;54:408–410
  24. Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism. 1994;78:790–794
  25. Libe R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research. 2007;13:844–850
  26. Yano T, Linehan M, Anglard P, et al. Genetic changes in human adrenocortical carcinomas. Journal of the National Cancer Institute. 1989;81:518–523
  27. Soon PS, Libe R, Benn DE, et al. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Annals of Surgery. 2008;247:157–164
  28. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 1991;64:849–859
  29. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature. 1993;365:764–767
  30. Matsuoka S, Edwards MC, Bai C, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development. 1995;9:650–662
  31. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Development. 1995;9:639–649
  32. Lam WW, Hatada I, Ohishi S, et al. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. Journal of Medical Genetics. 1999;36:518–523
  33. Wiedemann HR, Burgio GR, Aldenhoff P, et al. The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. European Journal of Pediatrics. 1983;140:5–12
  34. Hertel NT, Carlsen N, Kerndrup G, et al. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetic aspects. Acta Paediatrica. 2003;92:439–443
  35. Mesiano S, Mellon SH, Jaffe RB. Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. Journal of Clinical Endocrinology and Metabolism. 1993;76:968–976
  36. Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 1994;78:1444–1453
  37. Ilvesmaki V, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism. 1993;77:852–858
  38. Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 1998;83:1713–1720
  39. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism. 1997;82:2559–2565
  40. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. American Journal of Pathology. 2003;162:521–531
  41. de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism. 2005;90:1819–1829
  42. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993;362:749–751
  43. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature. 1993;362:747–749
  44. Weber MM, Auernhammer CJ, Kiess W, et al. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology. 1997;136:296–303
  45. Logie A, Boulle N, Gaston V, et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology. 1999;23:23–32
  46. Boulle N, Baudin E, Gicquel C, et al. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology. 2001;144:29–36
  47. Gao ZH, Suppola S, Liu J, et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism. 2002;87:1170–1176
  48. Liu J, Kahri AI, Heikkila P, et al. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. Journal of Clinical Endocrinology and Metabolism. 1997;82:1766–1771
  49. Kim AC, Reuter AL, Zubair M, et al. Targeted disruption of {beta}-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development. 2008;135:2593–2602
  50. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Science. 2003;94:225–229
  51. Naylor EW, Gardner EJ. Adrenal adenomas in a patient with Gardner's syndrome. Clinical Genetics. 1981;20:67–73
  52. Blaker H, Sutter C, Kadmon M, et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer. 2004;41:93–98
  53. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research. 2005;65:7622–7627
  54. Tadjine M, Lampron A, Ouadi L, et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clinical Endocrinology (Oxford). 2008;68:264–270
  55. S. Gaujoux, F. Tissier, L. Groussin, et al. Wnt/beta-catenin and cAMP/PKA signaling pathways alterations and somatic ss-catenin gene mutations in the progression of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2008; 93: 4135–4140.
  56. M. Tadjine, A. Lampron, L. Ouadi, et al. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clinical Endocrinology (Oxford) 2008; 69: 367–373.
  57. M. Doghman, J. Cazareth and E. Lalli. The Tcf/{beta}-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. Journal of Clinical Endocrinology and Metabolism 2008; 93: 3222–3225.
  58. Thakker RV. Multiple endocrine neoplasia–syndromes of the twentieth century. Journal of Clinical Endocrinology and Metabolism. 1998;83:2617–2620
  59. Schulte KM, Mengel M, Heinze M, et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. Journal of Clinical Endocrinology and Metabolism. 2000;85:441–448
  60. Heppner C, Reincke M, Agarwal SK, et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism. 1999;84:216–219
  61. Reincke M, Mora P, Beuschlein F, et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism. 1997;82:3054–3058
  62. Reincke M, Beuschlein F, Lalli E, et al. DAX-1 expression in human adrenocortical neoplasms: implications for steroidogenesis. Journal of Clinical Endocrinology and Metabolism. 1998;83:2597–2600
  63. Fassnacht M, Beuschlein F, Vay S, et al. Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. Journal of Endocrinology. 1998;159:35–42
  64. Igaz P, Wiener Z, Szabo P, et al. Functional genomics approaches for the study of sporadic adrenal tumor pathogenesis: clinical implications. Journal of Steroid Biochemistry and Molecular Biology. 2006;101:87–96
  65. Velazquez-Fernandez D, Laurell C, Geli J, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery. 2005;138:1087–1094
  66. Slater EP, Diehl SM, Langer P, et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology. 2006;154:587–598
  67. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology. 1989;13:202–206

PII: S1521-690X(08)00139-5

doi: 10.1016/j.beem.2008.10.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 261-271 , April 2009

Article Tools

* Image Usage & Resolution